Organic Active Ingredients TRIZ Cases

Pancreatic tumor treatment faces systemic toxicity and a desmoplasia barrier; coaxial polymer fibres provide controlled, prolonged local drug release.

Hydrolysis-prone amidine bonds are replaced with amide linkages, improving mannose retention and reproducibility in carbohydrate-polymer products.

Selective NaV1.6 compounds inhibit hyperactive neuronal sodium channels to control seizures while limiting neurotoxicity and cognitive effects.

Poorly water-soluble rifabutin is dissolved at high concentration with acid and solvent for parenteral, inhaled, or pulmonary delivery.

Hydrobromide, citrate, maleate, and other salts address Compound 1 solubility and stability limits in oral delivery.

Novel Encequidar crystal forms address handling, stability, and processing needs in formulations combined with Paclitaxel.

Tricyclic cores with pyrrole and amide groups support potent HBV inhibition, better solubility, and improved bioavailability.

A polymer scaffold releases therapeutic agents locally and over time, then bioresorbs within target tissue to limit repeated treatment burden.

Defined quinazoline substitutions tune kinase binding to balance cancer-treatment activity with selectivity across EGFR-mutant targets.

Amorphous nilotinib fumarate or tartrate dispersions with polymer carriers improve fasted-state bioavailability and reduce fed–fasted variability.

STING agonists activate innate immunity while checkpoint inhibitors boost T-cell activity against resistant cancers.

PROTAC compounds recruit E3 ubiquitin ligases to mark BCL6 for proteasomal degradation in cancer and autoimmune disease.

Rocaglamide derivatives block eIF4A-dependent translation to arrest MPNST cells, induce apoptosis, and suppress tumor growth.

Poor solubility and bioavailability limit chronic BK B2 antagonist therapy; a hydrophilic matrix tablet sustains release for at least 10 hours.

See how selective deuteration of MK2 pathway inhibitors improves metabolic stability while molecular tuning supports efficacy and specificity.

Diminazene-based small molecules are screened with biophysical assays to stabilize or destabilize RNA triple helices and probe recognition.

A moisture barrier plus steroid, antifungal, and antibiotic components addresses wetness, inflammation, fungal infection, and bacterial infection in diaper rash.

iPSC-derived megakaryocytes and platelets carry small-molecule or protein therapeutics, addressing donor shortages and limited targeting.

An injectable biodegradable nanogel forms in situ to stabilize drugs and extend release, reducing frequent dosing without surgery.

This case uses reduced, once-daily dextromethorphan–bupropion dosing to limit drug accumulation and adverse effects in renal impairment.

Targeted substituent changes preserve anti-tumor activity while improving camptothecin solubility and chemical stability.

Orally bioavailable ferroportin inhibitors address MDS iron overload and ineffective erythropoiesis while reducing the burden of parenteral treatment.

Hydrostatic pressure drives a cell-killing agent from the necrotic core through hypoxic tissue, while an antidote protects healthy cells.

See how Forms A, B, and C use XRPD and thermal profiles to control solid-state properties affecting BTK drug stability and solubility.

WRN helicase and ATPase inhibition offers a complementary approach for MSI-H/dMMR cancers facing limited checkpoint response and resistance.

By replacing monoclonal antibody mechanisms with chemical compounds, this approach targets PD-1/PD-L1 while reducing therapeutic complexity.

Crystallization of hemihydrate R-mandelate salts helps control impurities and improve consistency in ulotaront HCl manufacturing.

A dCas9-VPR complex activates TTN regulatory regions to restore protein expression across diverse DCM mutations without DNA cleavage.

Novel CRBN ligands vary Formula I substituents and side chains to preserve binding while degrading IKZF, WEE1, and CK1α.

Small-molecule TREM-1 inhibitors address short peptide lifespans while reducing proinflammatory cytokines and inflammatory responses.

These compounds inhibit plasma kallikrein to reduce thrombin generation, support clot dissolution, and limit reocclusion during fibrinolysis.

PLGA microparticles gradually release levothyroxine, extending pharmacological action from daily dosing to one administration lasting up to two months.

This amino acid combination raises plasma histidine and improves antioxidant defense to reduce liver steatosis, inflammation, and fat accumulation.

Drug-resistant RET variants such as G810R and Y806C can reduce inhibitor efficacy; heterocyclic compounds maintain targeted inhibition with favorable PK and safety profiles.

HFO-1234ze(E) and ethanol keep concentrated fluticasone particles dispersed, limiting flocculation and enabling stable single-actuation dosing.

AAK1-targeted compounds address mutation-limited muscular dystrophy therapies by promoting skeletal muscle growth and regeneration.

mPR agonists enhance GABAergic inhibition by increasing GABA receptor expression and phosphorylation to reduce brain excitability.

C19 restores centrosome organization and cardiomyocyte contractility in congenital dilated cardiomyopathy.

Cycloastragenol at 3–500 ng/ml is combined with antimicrobial, chelator, and excipient components to support telomerase activity and corneal tissue viability.

To address weak CDK2/Cyclin A selectivity, the compound tunes pyrazole substituents and ester structure to stall S phase or trigger apoptosis.

PIKfyve inhibitors disrupt lysosome homeostasis and coronavirus membrane trafficking, blocking infection below toxic concentrations in cultured cells.

Small-molecule compounds block SOS1–Ras-family binding, preventing KRas recycling into its active form for SOS1-associated cancer treatment.

See how pilocarpine eye formulations restore near vision through ciliary-muscle action while avoiding cumbersome lenses and surgery.

See how L-NIL-MDP peptide hydrogels replace repeated oral dosing with sustained intratumoral iNOS inhibition from a single injection.

Species-specific CRISPR targeting alters gut microbiota to modulate immune cell therapies while sparing related beneficial strains.

A local injectable blend of dexamethasone and ketorolac controls pain and swelling while reducing postoperative opioid use.

A pH-adjusted cleanser combines antibacterial and anti-inflammatory agents to manage blepharitis while reducing irritation around delicate eyelid skin.

Drug-resistant myeloma cells are targeted with LINC01432 LNA GapmeR inhibitors alongside melphalan to increase apoptosis and chemotherapy efficacy.

Defined heterocyclic rings help BET inhibitors bind selectively and covalently, reducing off-target effects and toxicity in therapy.

Co-crystallizing efinaconazole with pharmaceutically acceptable coformers addresses storage discoloration while supporting stable pharmaceutical formulations.